Fierce Biotech
Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for Chinese approval of a molecule that could reduce maintenance dose frequency.